Latest Eisai Stories
Company Appoints New Executive Leaders WOODCLIFF LAKE, N.J., March 10, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the appointments
- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time - SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
Patient Recruitment Now Underway at Treatment Centers Across the United States WOODCLIFF LAKE, N.J., Feb. 27, 2014 /PRNewswire/ -- Eisai Inc.
Preclinical Study Results Published in the Journal Molecular Cancer Therapeutics Show Sustained Efficacy of EZH2 Inhibitor in Animal Models CAMBRIDGE, Mass., Feb.
-- Eisai's Filing for Approval of BELVIQ as a Treatment for Chronic Weight Management Triggers $500,000 Milestone Payment to Arena -- SAN DIEGO, Feb.
Number of Insured Commercial Lives in the U.S. with Coverage for BELVIQ® Now Exceeds 50 Percent WOODCLIFF LAKE, N.J., Feb. 10, 2014 /PRNewswire/ -- Eisai Inc.
Tokyo, Feb 3, 2014 - (JCN Newswire) - Eisai Co., Ltd.
WOODCLIFF LAKE, N.J., Feb. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint.
FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.